Literature DB >> 30220489

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].

G Faviez1, E Bousquet1, A Rabeau1, I Rouquette2, S Collot3, C Goumarre4, N Meyer5, G Prevot1, J Mazieres6.   

Abstract

INTRODUCTION: Immune checkpoint inhibitors are becoming a standard treatment for many different cancers. Their toxicities are variable and include organ-specific dysimmune injuries and the development of systemic diseases. CASE REPORT: We report 3 cases of sarcoid-like granulomatosis that occurred during treatment of various types of primary cancer by immune checkpoint inhibitors: lung adenocarcinoma, small cell lung cancer and melanoma. The clinical presentation, radiologic pattern and severity of this toxicity were variable. The diagnosis was made on biopsy with pathological examination and exclusion of differential diagnoses, particularly infection. In such cases, immunotherapy should be discontinued and subsequent rechallenge discussed later. Systemic corticosteroids should be considered depending on the severity of symptoms.
CONCLUSIONS: Knowledge of this toxicity is crucial as the clinical signs and radiological patterns may suggest tumour progression.
Copyright © 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-PD-1/PD-L1; Granulomatose; Granulomatosis; Immune-related adverse events; Immunotherapy; Immunothérapie; Inhibiteurs de checkpoints immunitaires; PD-1/PD-L1 inhibitors; Toxicity; Toxicité

Mesh:

Substances:

Year:  2018        PMID: 30220489     DOI: 10.1016/j.rmr.2018.08.003

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  5 in total

1.  Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.

Authors:  Audrey Melin; Émilie Routier; Séverine Roy; Pauline Pradere; Jerome Le Pavec; Thibaut Pierre; Noémie Chanson; Jean-Yves Scoazec; Olivier Lambotte; Caroline Robert
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

2.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

3.  Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.

Authors:  Chanjuan Cui; Lei Deng; Wenqing Wang; Xiayang Ren; Yanfeng Wang; Wei Cui
Journal:  Front Oncol       Date:  2022-08-19       Impact factor: 5.738

Review 4.  The dark side of immunotherapy.

Authors:  Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal:  Ann Transl Med       Date:  2021-06

5.  Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis.

Authors:  Colm Kirby; Darragh Herlihy; Lindsey Clarke; Ronan Mullan
Journal:  BMJ Case Rep       Date:  2021-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.